BIOLUX P-IV CHINA ( BIOTRONIK )

Prospective, Multi-center, Non-randomized Clinical Trial of Passeo-18 Lux Drug Coated Balloon（DCB） in New and Non-stented Re-stenotic Lesions in the Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) in a Chinese Patient Population

Prospective, multi-center, non-randomized clinical trial with follow-up investigations at 1, 6 and 12 months. To confirm safety and efficacy of Passeo-18 Lux DCB in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in a Chinese patient population.

Study Overview

• Status: Completed
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Device: Paclitaxel releasing angioplasty balloon

Detailed Description

A prospective, multi-centre, non-randomized clinical trial with follow-up investigations at 1, 6 and 12 months. Approximately 158 subjects will be enrolled at 15 Chinese study sites. To confirm the safety and efficacy of the Passeo-18 Lux DCB for the interventional treatment of new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in a Chinese patient population.

• Study Type: Interventional
• Enrollment (Actual): 158
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200032
      • Fudan University Affiliated Zhongshan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years.
• Subject with documented diagnosis of peripheral arterial disease (PAD) classified as Rutherford class 2-3-4 in the superficial femoral artery (SFA) and/or proximal popliteal artery (PPA) above the knee, located in the arterial segment starting at least 1 cm beyond the common femoral artery (CFA) bifurcation between the superficial and profunda femoris arteries (proximal anatomical landmark) to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella (distal anatomical landmark).
• Subject able to walk without assistive devices (e.g. walker, cane).
• Female subjects of childbearing potential must have a negative pregnancy test ≤ 7 days before index procedure; Both male and female subjects are willing to use a reliable method of birth control for the duration of the study or must have documented adequate birth control.
• Signed and dated Patient Informed Consent (PIC) form.
• Subject understands and accepts the duration of the study and is able and willing to comply with all requirements, including follow-up visits and evaluations.
• Life expectancy, in the Investigator's opinion, of at least 12 months.
• Target lesion consists of a de novo or non-stented restenotic lesion with a ≥70% diameter stenosis.
• Lesion length≤ 200 mm.
• Reference vessel diameter ≥ 2 mm and ≤ 7 mm by visual estimate.
• Subject with ipsilateral/contralateral iliac disease that requires treatment during the index procedure can be included if treatment is successful (angiographic evidence of stenosis <30%). Iliac disease should be treated firstly by marketed devices excluding drug eluted stent and drug coated balloon.
• Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel [posterior tibial, anterior tibial, or peroneal arteries] is patent, defined as < 50% diameter stenosis).

Exclusion Criteria:

• Stroke or STEMI within 3 months prior to index procedure.
• Either local or systemic thrombolytic therapy within 48 hours prior to index procedure.
• Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT).
• Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/anti-platelet therapies, and/or paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.
• Breastfeeding women.
• Chronic renal insufficiency with serum creatinine > 2.5 mg/dL within 14 days prior to index procedure.
• White blood cell count (WBC) < 3,000 cells/mm3 within 14 days prior to index procedure.
• Platelet count < 80,000 cells/mm3 or > 700,000 cells/mm3 within 14 days prior to index procedure.
• Known or suspected active systemic infection evidenced by WBC > 14.0 (14000/mm3) within 14 days prior to index procedure.
• Diagnosed with bleeding diatheses or hypercoagulable state.
• Subject is enrolled in any investigational device, drug or biologic study.
• Any major (e.g., cardiac. peripheral, abdominal) surgical procedure or planned intervention performed within 30 days prior to the index procedure.
• Any major (e.g., cardiac. peripheral, abdominal) elective procedure or intervention within 30 days post index procedure.
• Target lesion known in advance of enrollment to require treatment with alternative therapy such as (drug-eluting) stent, laser, atherectomy, cryoplasty, re-entry devices, cutting/scoring balloon, brachytherapy. Use of embolic protection devices is also prohibited.
• Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure.
• Presence of additional lesions in the target vessel that require treatment during index procedure but do not meet the inclusion criteria.
• Complete occlusion lesion> 100mm.
• Target lesion is an in-stent or post-DCB restenosis or has been previously treated with bypass surgery.
• Lesion within or adjacent to an aneurysm.
• Acute or sub-acute thrombus in the target vessel.
• Angiographic evidence of severe calcification.
• Failure to successfully cross the target lesion with a guide wire.
• Pre-dilation resulted in a major (≥ Grade D) flow-limiting dissection (observed on 2 orthogonal views) or residual stenosis > 70% or translesional peak gradient > 10mm Hg.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Paclitaxel releasing angioplasty balloon; Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)

Device: Paclitaxel releasing angioplasty balloon; Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major Adverse Events	a composite of device- and procedure-related mortality, major target limb amputation and clinically-driven target lesion revascularization（TLR） within 12-months post-initial procedure.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Death of any cause	the all-cause mortality of subjects at 30 days, 6 months and 12 months after index procedure	30 days, 6 and 12 months
Target lesion revascularization	TLR,Target lesion revascularization.In the subjects experiencing target lesion revascularization, the two revascularizations were both judged as clinically driven target lesion revascularization.	30 days, 6 and 12 months
Clinically-driven target lesion revascularization	Defined as any re-intervention at the target lesion due to symptoms or drop of ABI/TBI of≥20% or >0.15 when compared to post-procedure baseline ABI/TBI（Ankle Brachial Index/Toe Brachial Index）. Clinically driven TLR will be adjudicated by an independent Clinical Event Committee	30 days, 6 and 12 months
Target vessel revascularization	TVR,Target vessel revascularization.The target vessel revascularization of subjects at 30 days, 6 months, and 12 months after index procedure.Defined as any re-intervention at the target vessel due to symptoms or drop of ABI/TBI of≥20% or >0.15 when compared to post-procedure baseline ABI/TBI. Clinically driven TVR will be adjudicated by an independent Clinical Event Committee	30 days, 6 and 12 months
Clinically-driven target vessel revascularization	Defined as any re-intervention at the target vessel due to symptoms or drop of ABI/TBI of≥20% or >0.15 when compared to post-procedure baseline ABI/TBI. Clinically driven TVR will be adjudicated by an independent Clinical Event Committee	30 days, 6 and 12 months
Major target limb amputation	Surgical removal of tissue within the affected limb.; Above-knee amputation: amputation at a point above the knee; Below-knee amputation: amputation at a point below the knee	30 days, 6 and 12 months
Thrombosis at the target lesion site	Rapidly developing into total occlusion due to thrombosis confirmed by sudden onset of symptoms and recorded by Doppler ultrasound and/or angiography. Thrombosis can be classified as acute (<1 day), subacute (1-30 days) and late (> 30 days).	30 days, 6 and 12 months
Primary sustained clinical improvement	Primary sustained clinical improvement at 6 months and 12 months after index procedure is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without further endovascular or surgical revascularization procedure(s) at target lesion.	6 and 12 months
Secondary sustained clinical improvement	Secondary sustained clinical improvement at 6 months and 12 months after surgery defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including further endovascular or surgical revascularization procedures at target lesion.	6 and 12 months
Duplex-defined binary restenosis (PSVR > 2.4) of the target lesion	Binary restenosis of the target lesion determined by Duplex ultrasound at the time of re-intervention before 6 months and 12 months after index procedure or any prescheduled time point was judged by PSVR > 2.4.	6 and 12 months
Walking capacity assessment by Walking Impairment Questionnaire	Changes in walking ability assessed with the Walking Impairment Questionnaire (WIQ) at baseline, 30 days, 6 months, and 12 months after index procedure.	at baseline, 30 days, 6 and 12 months
Walking distance as assessed by 6 Minute Walk Test	Changes in the walking distance assessed with the 6-minute walking test (6MWT) at baseline, 30 days, 6 months, and 12 months after index procedure.	at baseline, 30 days, 6 and 12 months
Quality of life assessment by EuroQol Five Dimensions（EQ5D） questionnaire	Changes in quality of life assessed with the EQ5D questionnaire at baseline, 30 days, 6 months, and 12 months after index procedure.	at baseline, 30 days, 6 and 12 months
Device success	Device success referred to the intact investigational device successfully performing delivery, balloon inflation, deflation, and withdrawal without bursting below the rated burst pressure (RBP).	during the procedure
Procedural success	Procedural success referred to residual stenosis ≤ 50% (for subjects without stent) or ≤ 30% (for subjects with stent) as accessed by the core laboratory.	during the procedure
Clinical success	Clinical success, defined as procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge.	during the hospitalization

Collaborators and Investigators

• Sponsor: Biotronik (Beijing) Medical Device Ltd.
• Investigators: Principal Investigator: Weiguo Fu, Fudan University

Publications and helpful links

General Publications

• Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0. Epub 2013 Aug 1.

Helpful Links

• test link

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2016
• Primary Completion (Actual): August 1, 2020
• Study Completion (Actual): August 1, 2020

Study Registration Dates

• First Submitted: September 8, 2016
• First Submitted That Met QC Criteria: September 22, 2016
• First Posted (Estimated): September 23, 2016

Study Record Updates

• Last Update Posted (Actual): August 21, 2023
• Last Update Submitted That Met QC Criteria: August 17, 2023
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Arterial Disease; Peripheral Vascular Diseases; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: C1303

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO